Biovica International AB (publ) (BIOVIC-B.ST)
SEK 0.79
(12.29%)
SEK 0.79
(12.29%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 34.76 Million SEK | 3.31% |
| 2022 | 33.65 Million SEK | 22.18% |
| 2021 | 27.54 Million SEK | 175.73% |
| 2020 | 9.98 Million SEK | -17.05% |
| 2019 | 12.04 Million SEK | 37.43% |
| 2018 | 8.76 Million SEK | 24.14% |
| 2017 | 7.05 Million SEK | 25.19% |
| 2016 | 5.63 Million SEK | 73.26% |
| 2015 | 3.25 Million SEK | -65.54% |
| 2014 | 9.44 Million SEK | 134.67% |
| 2013 | 4.02 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 24.58 Million SEK | -29.29% |
| 2023 Q4 | 34.76 Million SEK | 55.98% |
| 2023 Q3 | 22.29 Million SEK | -3.96% |
| 2023 FY | 34.76 Million SEK | 3.31% |
| 2023 Q1 | 27.92 Million SEK | -17.02% |
| 2023 Q2 | 23.2 Million SEK | -16.89% |
| 2022 Q1 | 28.26 Million SEK | 2.62% |
| 2022 Q4 | 33.65 Million SEK | 19.73% |
| 2022 Q2 | 25.92 Million SEK | -8.27% |
| 2022 FY | 33.65 Million SEK | 22.18% |
| 2022 Q3 | 28.1 Million SEK | 8.41% |
| 2021 FY | 27.54 Million SEK | 175.73% |
| 2021 Q2 | 8.1 Million SEK | 8.03% |
| 2021 Q3 | 11.5 Million SEK | 42.02% |
| 2021 Q1 | 7.5 Million SEK | -24.91% |
| 2021 Q4 | 27.54 Million SEK | 139.34% |
| 2020 Q2 | 9.8 Million SEK | -12.08% |
| 2020 FY | 9.98 Million SEK | -17.05% |
| 2020 Q4 | 9.98 Million SEK | -8.13% |
| 2020 Q3 | 10.87 Million SEK | 10.87% |
| 2020 Q1 | 11.15 Million SEK | -7.37% |
| 2019 Q4 | 12.04 Million SEK | 0.03% |
| 2019 FY | 12.04 Million SEK | 37.43% |
| 2019 Q1 | 8.92 Million SEK | 1.81% |
| 2019 Q2 | 11.69 Million SEK | 31.12% |
| 2019 Q3 | 12.03 Million SEK | 2.92% |
| 2018 Q2 | 6.23 Million SEK | 1.88% |
| 2018 FY | 8.76 Million SEK | 24.14% |
| 2018 Q4 | 8.76 Million SEK | 24.51% |
| 2018 Q3 | 7.03 Million SEK | 12.95% |
| 2018 Q1 | 6.11 Million SEK | -13.36% |
| 2017 FY | 7.05 Million SEK | 25.19% |
| 2017 Q1 | 4.87 Million SEK | -13.52% |
| 2017 Q4 | 7.05 Million SEK | 18.88% |
| 2017 Q3 | 5.93 Million SEK | 21.71% |
| 2017 Q2 | 4.87 Million SEK | 0.04% |
| 2016 Q4 | 5.63 Million SEK | 0.0% |
| 2016 Q1 | - SEK | -100.0% |
| 2016 FY | 5.63 Million SEK | 73.26% |
| 2016 Q2 | 3.76 Million SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 Q4 | 3.25 Million SEK | -18.57% |
| 2015 Q3 | 3.99 Million SEK | 0.0% |
| 2015 FY | 3.25 Million SEK | -65.54% |
| 2014 FY | 9.44 Million SEK | 134.67% |
| 2013 FY | 4.02 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alzinova AB (publ) | 9.33 Million SEK | -272.597% |
| Amniotics AB (publ) | 10.54 Million SEK | -229.639% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -685.517% |
| BioArctic AB (publ) | 139.5 Million SEK | 75.078% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 97.78% |
| Genovis AB (publ.) | 98.04 Million SEK | 64.54% |
| LIDDS AB (publ) | 3.75 Million SEK | -825.639% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 71.957% |
| OncoZenge AB (publ) | 1.69 Million SEK | -1946.321% |
| Saniona AB (publ) | 86.08 Million SEK | 59.612% |
| Simris Alg AB (publ) | 148.93 Million SEK | 76.657% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 14.91% |
| AcouSort AB (publ) | 10.37 Million SEK | -235.007% |
| Active Biotech AB (publ) | 13.4 Million SEK | -159.455% |
| Camurus AB (publ) | 414.81 Million SEK | 91.619% |
| Cantargia AB (publ) | 54.97 Million SEK | 36.753% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -805.862% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | -87.991% |
| Mendus AB (publ) | 51.22 Million SEK | 32.129% |
| Kancera AB (publ) | 17.97 Million SEK | -93.386% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -200.519% |
| Lipum AB (publ) | 7.53 Million SEK | -361.223% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -574.04% |
| NextCell Pharma AB | 13.68 Million SEK | -153.977% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 92.79% |
| Xintela AB (publ) | 14.01 Million SEK | -148.07% |
| Ziccum AB (publ) | 6.38 Million SEK | -444.255% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -152.455% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -1373.802% |
| Isofol Medical AB (publ) | 19.16 Million SEK | -81.418% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 51.612% |
| CombiGene AB (publ) | 4.15 Million SEK | -736.55% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 51.114% |
| Intervacc AB (publ) | 21.68 Million SEK | -60.364% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 67.384% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | -0.474% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | -30.174% |
| Corline Biomedical AB | 6.78 Million SEK | -412.108% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 43.337% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -115.716% |
| Aptahem AB (publ) | 8.99 Million SEK | -286.393% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 24.714% |
| Fluicell AB (publ) | 8.91 Million SEK | -289.983% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -197.969% |
| Abliva AB (publ) | 16.78 Million SEK | -107.181% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 83.799% |
| 2cureX AB (publ) | 2.93 Million SEK | -1084.566% |
| I-Tech AB | 16.2 Million SEK | -114.545% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 97.068% |
| Cyxone AB (publ) | 4.69 Million SEK | -640.669% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -160.857% |
| Biosergen AB | 5.08 Million SEK | -583.717% |
| Nanologica AB (publ) | 79.32 Million SEK | 56.173% |
| SynAct Pharma AB | 51.83 Million SEK | 32.926% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -337.376% |
| BioInvent International AB (publ) | 90.45 Million SEK | 61.563% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -569.247% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 80.855% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -1837.96% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -172.811% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -378.884% |